Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer
Covered in this story
Call it yourself
No calls on $VCYT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Veracyte Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.